Skip to main content Skip to main navigation menu Skip to site footer

Successful alopecia universalis treatment with the combination of cyclosporine and oral corticosteroid: a case report


Background: Alopecia universalis is an autoimmune condition on hair follicles with the characteristics of ovoid or round-shaped hair loss (focal) that develops into multiple hair losses and is the most severe form of alopecia. The pathogenesis of alopecia universalis is unclear. However, the most accepted hypothesis is based on the immunologic factor, especially T-cell mediated autoimmune process.

Case: A 19-year-old male Indonesian complained of hair loss all over his body. Efflorescence of the whole body showed an alopecia patch. The Severity of Alopecia Tool (SALT) score showed 100%. Skin dermoscopy indicated yellow dots. The patient was given 8 mg of intraoral methylprednisolone every 8 hours and 100 mg of intraoral cyclosporine every 12 hours for four weeks and slowly tapering off. The patient experienced acneiform eruption and was topically treated with 2% sulfur lotion every 12 hours. After 51 days of observation, an improvement was found in terminal hair growth on the head, eyelashes, and eyebrows, visible growth of vellus hair on the body, and a SALT score of 40%.

Conclusion: Alopecia universalis is rare and can cause significant damage and psychological pressure to the affected individuals. Treatment with corticosteroid and cyclosporine resulted in good therapy response.


  1. Beigi P. Alopecia Totalis/Universalis. In: Alopecia Areata: A Clinician’s Guide. 2018. p. 13–5.
  2. Grenier PO, Veillette H. Treatment of alopecia universalis with oral alitretinoin: A case report. JAAD Case Reports. 2017;3(2):140–2.
  3. Thomas E, Kadyan R. Alopecia areata and autoimmunity: a clinical study. Indian J Dermatol. 2008;53(2):79–4.
  4. Ciptasari NWE. Role of PRP (platelet-rich plasma) in alopecia areata: A literature review. Bali Med J. 2020;9(3):731–6.
  5. Messenge A, McKillop J, Farrant P, McDonagh A, Sladden M. British association of dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916–26.
  6. Alkhalifah A, Alsantali A, Wang E, McElwee K, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62:177–88.
  7. Barahmani N, Schabath M, Duvic M, Registry N. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol. 2009;61(4):581–91.
  8. Lee H, Gwillim E, Patel K, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675–82.
  9. Anonim. Dermatology and Venereology Cosmetic Division Outpatient Registry of Sanglah General Hospital 2019 - 2022. 2022.
  10. Amin S, Sachdeva S. Alopecia areata: A review. J Saudi Soc Dermatology Dermatologic Surg. 2013;17(2):37–45.
  11. Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study. Int J Dermatol. 2018;57(12):1464–70.
  12. Açikgöz G, Çalişkan E, Tunca M, Yeniay Y, Akar A. The effect of oral cyclosporine in the treatment of severe alopecia areata. Cutan Ocul Toxicol. 2014;33(3):247–52.
  13. Birol A, Erkek E, Tuncez F, Saylam Kurtipek G, Baǧci Y, Koçak M. The Efficacy of Intermittant Low-Dose Systemic Corticosteroid in the Treatment of Alopecia Areata. Turkish J Med Sci. 2004;34(1):55–8.
  14. Otberg N, Shapiro J. Alopecia Areata. In: Kang S, Amagi M, Bruckner A, Enk A, Margolis D, McMichael A, et al., editors. Fitzpatrick’s Dermatology 9th Edition. New York: Mc Graw Hill Education; 2019. p. 1517–23.
  15. Cho SK, Craiglow BG. Dupilumab for the treatment of alopecia areata in children with atopic dermatitis. JAAD Case Reports. 2021;16(August):82–5.
  16. Smogorzewski J, Sierro T, Compoginis G, Kim G. Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Reports. 2019;5(2):116–7.
  17. Dhurat R. Utility of trichoscopy. Indian J Dermatopathol Diagnostic Dermatology. 2018;5(2):89–96.
  18. Whiting D. Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2003;139(12):1555–9.
  19. Alessandrini A, Starace M, Bruni F, Brandi N, Baraldi C, Misciali C, et al. Alopecia Areata Incognita and Diffuse Alopecia Areata: Clinical, Trichoscopic, Histopathological, and Therapeutic Features of a 5-Year Study. Dermatol Pract Concept. 2019;9(4):272–7.
  20. Errichetti E, Stinco G. Dermoscopy in General Dermatology: A Practical Overview. Vol. 6, Dermatology and Therapy. Springer Healthcare; 2016. 471–507 p.
  21. Bains P, Kaur S. Clinical and dermoscopic patterns of childhood alopecia areata in a tertiary care centre in North India. Int J Res Dermatology. 2021;7(6):811–5.
  22. Jha A, Udayan U, Amar AK, Chaudhary R. Dermoscopy of alopecia areata in restrospective analysis. Dermatol Pract Concept. 2017;7(2):53–7.
  23. Abraham L, Torres F, Azulay-Abulafia L. Dermoscopic clues to distinguish trichotillomania from patchy alopecia areata. An Bras Dermatol. 2010;85(5):723–6.
  24. You HR, Kim SJ. Factors associated with severity of alopecia areata. Ann Dermatol. 2017;29(5):565–70.
  25. Sardesai V, Prasad S, Agarwal T. A Study to Evaluate the Efficacy of Various Topical Treatment Modalities for Alopecia Areata. Int J Trichology. 2012;4(4):265–70.
  26. Strazzulla L, Wang E, Avila L, Lo Sicco K, Brinster N, Christiano A, et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24.
  27. Özlü E, Karadağ A. Drug-induced Acneiform Eruptions. In: Kartal S, Gonul M, editors. Acne and Acneiform Eruptions [Internet] [Internet]. London: IntechOpen; Available from:
  28. Kim B, Min S, Park K, Choi J, Park S, Youn S, et al. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatolog Treat. 2008;19(4):216–20.
  29. Nowaczyk J, Makowska K, Rakowska A, Sikora M, Rudnicka L. Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review. Dermatol Ther (Heidelb). 2020;10(3):387–99.
  30. Jeyaraj K, Krishnakumar M, Sivakumar V, Venkatakrishnan L. A Case Report on Steroid Induced Acneiform Eruptions. Indian J Pharm Pract. 2017;10(1):65–7.
  31. Liu H, Yu H, Xia J, Liu L, Liu GJ, Sang H, et al. Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne. Cochrane Database Syst Rev. 2020;2020(5):1–257.
  32. Lai VWY, Chen G, Gin D, Sinclair R. Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J Am Acad Dermatol. 2019;81(3):694–701.

How to Cite

Darmaputra, I. G. N., Tirka, P. S. W., Ramaswari, P. A. Y., & Mahariski, P. A. (2022). Successful alopecia universalis treatment with the combination of cyclosporine and oral corticosteroid: a case report. Bali Medical Journal, 11(2), 633–637.




Search Panel

I Gusti Nyoman Darmaputra
Google Scholar
BMJ Journal

Putu Shinta Widari Tirka
Google Scholar
BMJ Journal

Putu Ayuni Yayas Ramaswari
Google Scholar
BMJ Journal

Pande Agung Mahariski
Google Scholar
BMJ Journal